Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.31 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.31 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.31 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 2/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10186174 | 1.00 | KMT2A (0.33) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL15074250 | 1.00 | KMT2A (0.33) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL13471112 | 0.83 | MMP8 (0.34) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL19906319 | 0.82 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15499370 | 0.82 | GRIN2D (0.32) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL15497665 | 0.81 | SLC6A3 (0.37) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL18671825 | 0.81 | HTT (0.34) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL15070172 | 0.81 | TSHR (0.33) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL15841063 | 0.81 | HTT (0.34) | KMT2AHTTGRIN2DGRIN3BGRIN1 | |
| SCHEMBL19866522 | 0.81 | HTT (0.34) | KMT2AHTTGRIN2DGRIN3BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3013340-B9 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| EP-3013340-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | JANSSSEN BIOPHARMA, INC. (US) | 2021-12-23 | — | — | US | disclosed |
| EP-3912984-A1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | Janssen BioPharma, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3797782-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTIONS | Janssen BioPharma, Inc. (US) | 2021-03-31 | — | — | EP | disclosed |
| EP-2935303-B1 | 4'-FLUORO-NUCLEOSIDES, 4'-FLUORO-NUCLEOTIDES AND ANALOGS THEREOF FOR THE TREATMENT OF HCV | JANSSEN BIOPHARMA INC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3160476-B1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF FOR USE IN THE TREATMENT OF VIRAL INFECTION | JANSSEN BIOPHARMA INC (US) | 2020-09-30 | — | — | EP | disclosed |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | Janssen Pharmaceuticals, Inc. | 2020-09-03 | — | — | US | disclosed |
| US-RE48171-E1 | Substituted nucleosides, nucleotides and analogs thereof | Janssen Biopharma, Inc. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | JANSSEN PHARMACEUTICA NV | 2015-01-01 | — | — | US | disclosed |
| US-8871737-B2 | Substituted nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8772474-B2 | Cyclic nucleotide analogs | ALIOS BIOPHARMA, INC. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | VERTEX PHARMACEUTICALS INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179910-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | KMT2A 3429/4885HTT 2179/4885GRIN2D 4759/4885 |
| US-20140179627-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NUDT1, NT5C2 | KMT2A 3429/4885HTT 2179/4885GRIN2D 4759/4885 |
| US-20130165400-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, ADAR | KMT2A 2676/4885HTT 3906/4885GRIN2D 4580/4885 |
| US-20130164261-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | KMT2A 1930/4885HTT 1529/4885GRIN2D 4857/4885 |
| US-20120071434-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NUDT1, TYMP | KMT2A 1930/4885HTT 1529/4885GRIN2D 4857/4885 |
| US-20200277321-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | KMT2A 4449/4885HTT 4136/4885GRIN2D 3731/4885 |
| US-20210395288-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALAOGS THEREOF | PNP, RNGTT, NT5C3B | KMT2A 4449/4885HTT 4136/4885GRIN2D 3731/4885 |
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | KMT2A 1598/4885HTT 2340/4885GRIN2D 4820/4885 |
| US-20130252920-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A THIONUCLEOTIDE ANALOG | TYMP, POLN, POLRMT | KMT2A 3022/4885HTT 150/4885GRIN2D 4874/4885 |
| US-11149049-B2 | Substituted nucleosides, nucleotides and analogs thereof | PNP, TYMP, SLC29A1 | KMT2A 4562/4885HTT 3741/4885GRIN2D 3997/4885 |
| US-20150005251-A1 | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF | PNP, NT5C3B, NT5C2 | KMT2A 3109/4885HTT 3644/4885GRIN2D 4711/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.